Compartment Syndrome of LegPhase 1NCT04113954
Detecting Compartment Syndrome Pain in the Presence of Regional Anesthesia in Healthy Volunteers
A Phase 1 study testing Mepivacaine Injection in people with Compartment Syndrome of Leg and Healthy, run by Brigham and Women's Hospital at 1 site in United States.
Trial summary
The goal of the study is to determine how different types of Regional Anesthesia (nerve blocks) can be helpful to patients with lower extremity trauma who develop compartment syndrome (an increased pressure in the fascial compartments) which can occur after injury to the leg. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Compartment Syndrome of Leg, Healthy
- What is being tested?
- Mepivacaine Injection
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 42 participants
- Where
- 1 siteUnited States
- Study dates
- 29 Sep 2020to 6 Apr 2021
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years old, ≤ 65 years old
- BMI < 35
- Able to speak and understand English
- Willingness to undergo psychophysical testing
- Willingness to have nerve block performed
Who cannot join
- Ongoing acute or chronic pain in lower extremities
- Diagnosis of neuropathy
- Diagnosis of diabetes
- History of chronic opioid use (having an opioid prescription > 30 days)
- Loss of any limb
- Currently pregnant
Show all 10Show fewer
- Any skin conditions or breakdown of skin affecting lower extremities
- Current history of peripheral arterial disease
- History of blood clot in any lower extremity
- Current smoking/vaping of nicotine or illicit substances including marijuana
Trial locations and contacts
1 site in 1 country.
United States1 site
Brigham and Women's Hospital
Boston, Massachusetts, 02115
About this study
The goal of the study is to determine how different types of Regional Anesthesia (nerve blocks) can be helpful to patients with lower extremity trauma who develop compartment syndrome (an increased pressure in the fascial compartments) which can occur after injury to the leg.
This is a prospective, randomized study in healthy volunteers, who will undergo testing of the leg using a cuff inflation system, involving quantitative sensory testing (QST), questionnaire completion, with ultrasound scanning and nerve blocks in a supervised, monitored setting (BWH Clinical Investigation Center).
Read more
Specific Aims
- Determine the effect of adductor canal-saphenous nerve block (ACB) and popliteal-fossa nerve block (SNB-PF) vs no block on pressure and ischemic pain in a model of compartment syndrome.
- Hypothesis: There will be minimal or no change in pressure pain threshold and tolerance and pain ratings with ACB alone
- Hypothesis: There will be an increase in pressure pain threshold and tolerance and decrease in pain ratings with ACB plus popliteal-fossa nerve block (SNB-PF), compared to no block
- Determine the concentration dependence of SNB-PF effect on pressure and ischemic pain by comparing increasing doses of local anesthetic.
- Hypothesis: There will be a greater increase in pressure pain threshold and tolerance and great decrease in pain ratings with 1.5% mepivacaine than with 0.375% mepivacaine.
Read the detailed description
Please complete the survey (copy and paste into new link). https://redcap.partners.org/redcap/surveys/?s=D4A4TN9TDL We will not contact you if the survey is incomplete.
Please contact us via email (ykchen@partners.org) about this study with subject line "Interested in participating in Compartment Syndrome Study"
Screening and Enrollment:
Healthy volunteers will be recruited, and all interested individuals will be invited to contact study staff to hear more about the study requirements and undergo a brief phone screen to determine eligibility. After their initial phone screen with study staff, interested subjects meeting eligibility requirements will be provided with an electronic copy of the consent form, perform a video consent, and schedule a study visit, to be conducted in the Clinical Investigation Center at Brigham and Women's Hospital. A 5 hour, 1 office visit is required.
All subjects will also undergo a survey-based COVID screen within 24 hours prior to the study.
Study day:
Immediately upon arrival for their study appointment, the physician investigator will go through the consent form in detail with each potential participant, and they will also be given a chance to read it thoroughly and have questions answered. Special care will be taken during the consent process to ensure subjects are fully competent and understand the nature of the questionnaires and testing procedures, including a brief demonstration of the devices and testing done. If agreeable to the study procedures after having questions answered, participants will provide informed consent. Each participant will be assigned a random ID number, and data will be collected, entered, and analyzed by ID number only. The subject's status as a patient will be unaffected by his/her decision to participate. If subject decides against participation at this point, they will be reimbursed for their time ($20).
Enrolled participants will complete basic deidentified demographic, clinical, psychosocial, and pain questionnaires. Brief validated questionnaires will include the PROMIS anxiety, depression, and sleep disturbance short forms, Pain Catastrophizing Scale (PCS), situational pain catastrophizing scale (sPCS), Brief Symptom Index, Fibromyalgianess scale, Brief Pain Inventory, Positive and Negative Affect Schedule, and pain coping strategies questionnaire.
After completing questionnaires, subjects will lie on a stretcher, with head of bed elevated to 30-45 degree angle according to comfort, with legs and feet exposed for testing.
QST testing Pressure pain threshold: Pressure algometry is the most commonly used test for static mechanical pressure sensation in the skin and in deep tissues. Pressure algometers deliver a firm and quantifiable pressure through a flat base applied to the skin. The electronic pressure algometer that we will use (Wagner Instruments) is a hand-held algometer utilizing a pressure-sensitive strain gauge, covered by a 0.5 cm2 circular probe. The probe is covered with a soft polypropylene disk, to avoid injury to the skin. The pressure applied through the probe is transduced, amplified, and converted to electrical reading on a digital display. The pressure will be slowly increased (1 lb/s) and the participant will be asked to note when they first feel pain and when they want the pressure to stop , which will be recorded as the pressure pain threshold and tolerance, respectively.120 This process will be repeated on the trapezius and the forearm, alternating between sides of the body with 20 seconds between measurements.
Pin Prick: This tests the detection and intensity of sharp type pain. In addition, it is often used as a modality to test temporal summation of pain with repeated stimuli. The conductor of the test will touch the participant on the finger with weighted mechanical probes in ascending order (64 mN, 128 mN, 256 mN, 512 mN), making sure to keep the probe perpendicular to the skin, and allowing the full weight to be resting on this point (i.e. the weight moves within the barrel), but without touching the barrel/cylinder itself to the skin. The participant will be instructed to rate the pain (0-10) of each stimulation. The conductor will make note of the lowest weight pin prick the participant indicated caused a 1-3 out of 10 pain. Then the conductor will perform the test of temporal summation to repeated punctate stimuli, which is considered an index of central pain-faciliatory processes. The pin prick weight that the participant noted was a 1-3 out of 10 pain is applied to the skin of the dorsal fingers at a frequency of 1Hz. Ten stimuli are applied, and the patient will be asked to rate the sensation of pain from the fifth, and tenth stimulus, as well as 15 seconds after the end of the stimulus train (PAS). The wind-up phenomenon occurs with progressive increase evoked pain with repeated stimulation and represents an index of central sensitization. Testing order will be performed on each hand, bilaterally, and on each foot.
Pressure Pain Threshold Assessment:
Pressure pain will be assessed through response to cuff pressure algometry (CPA). Tonic, deep-tissue, mechanical stimulation will be applied using a Hokanson rapid cuff inflator, which allows specific calibrated pressures to by administered and held for defined time periods. Using an adjustable cuff (similar to standard blood pressure cuff) wrapped around the leg, centered around the largest diameter of the gastrocnemius muscle, pressure will be increased by turning a manual dial at a rate of approximately 10-20 mmHg/second until the subject first feels pressure, and thereafter at approximately 5-10 mmHg/s, at which time subject will be asked to note when they first start feeling pain and then when they feel as though the pain is a 4, 6, 8 and 10 out of 10 VAS score (0 = no pain, 10 = worst pain), after which the cuff will be immediately deflated. Participants will be given a break. Cuff pressure at each of these points will be recorded 3 times for each leg to determine baseline pain thresholds.
Ischemic Pain Assessment:
The cuff will be re-inflated to the subject's average pressure previously determined to produce 4 out of 10 pain for that leg, and held for 5 minutes. A pulse oximeter will be placed on the big toe to monitor ischemia (pulse oximetry wave expected to disappear). Subjects will be asked for pain score at rest every 30 seconds, and pain score on passive stretch of gastrocnemius every 60 seconds. The participant will be reminded immediately before cuff inflation that they may ask for the pressure cuff to be deflated at any time, in which case this time will be recorded. Subjects will be asked to indicate the presence of tingling (paresthesias), and will rate pain at rest 30 and 60 seconds following cuff deflation (painful after sensations), as well as pain with passive stretch of gastrocnemius at 60 seconds after cuff deflation.
There will be a 1 minute break, then the cuff pressure will be inflated to a pressure corresponding to the next pain level as initially identified on the averaged baseline testing (ex: if pressure 4/10 was 100 mmHg and 6/10 was 150 mmHg, cuff pressure will first be held at 100 mmHg and held for 5 minutes, followed by a 1 minute break, and then reinflated at 150 mmHg and held for 5 minutes, followed by 1 minutes break, etc.). The above procedure will be repeated for cuff pressure at 6/10, 8/10, and 10/10. This will be done first on the "control leg" and then on the "block leg" prior to the nerve block placement. Subjects will be reminded that they may discontinue the cuff inflation at any point, and the time of cuff inflation recorded.
IV placement:
A 20 g IV will be placed prior to the start of any nerve block procedure. Site of IV placement will be cleaned with alcohol swab and initially anesthetized with 1% lidocaine administered through a small needle to allow greater comfort with IV placement.
Nerve Blocks:
Saphenous Nerve Block (ACB):
Subjects will lie supine with block leg slightly abducted. Standard monitors will be applied for vital monitoring (continuous pulse oximetry, EKG, blood pressure cuff every 5 minutes), and this monitoring continued until 20 minutes after block completion. Using sterile technique (cleaning of skin with chloroprep, sterile gloves, mask, sterile cap, sterile needle, sterile ultrasound probe cover and sterile gel), an ultrasound-guided approach will be used to identify the saphenous nerve and surrounding sonographic landmarks (sartorius muscle, vastus medialis, femoral artery, femoral vein, and adductor magnus). With a small needle, a small skin wheal of 1 cc of 1% lidocaine will be used to anesthetize the skin. Afterwards a standard 21 g, 10 cm block needle will be inserted and directed under ultrasound guidance to the saphenous nerve location. Aspiration on block syringe will be performed to confirm that needle tip is not within a vascular structure to avoid intraarterial or venous injection of local anesthetic. Incremental injection (5 cc at a time) of 1.5% mepivacaine will follow, with a total of 10 cc (150 mg) deposited around the saphenous nerve.
Popliteal sciatic Nerve Block (SNB-PF): (for dual nerve block group only) Participant will lie supine, with leg elevated to allow access to posterior leg for US scanning. Using sterile technique, an ultrasound-guided approach will be used to identify the common peroneal nerve and tibial nerve at the level of the popliteal fossa, and surrounding sonographic landmarks (femur, popliteal artery, and popliteal vein). The common peroneal and tibial nerves will be followed proximally by scanning proximally along the leg with the ultrasound until they form a unitary nerve (sciatic). With a small needle, a small skin wheal of 1 cc of 1% lidocaine will be used to anesthetize the skin of the lateral level at this level. Afterwards a standard 21 g, 10 cm block needle will be inserted and directed under ultrasound guidance to the sciatic nerve. Aspiration on block syringe will be performed to confirm that needle tip is not within a vascular structure to avoid intraarterial or venous injection of local anesthetic. Incremental injection (5 cc at a time) of 0.375% or 1.5% mepivacaine will follow, with a total of 15 cc (56.25 mg or 225 mg) deposited around the sciatic nerve.
Expected timeline Pressure pain threshold assessment will take approximately 3 minutes and Ischemic pain assessment approximately 30 minutes (5 minutes per inflation pressure with 1 minute for rest in between). Each assessment will be taken at baseline and 20 minutes after nerve block completion to allow full effect. Ultrasound measures of compartment pressures will be assessed before, during, and after pressure and ischemic pain assessment.
Resolution of Nerve block: Nerve blocks with mepivacaine are expected to be resolved within 4-6 hours, but monitoring will continue beyond this time as some normal variation in resolution may occur between individuals. Subjects will only be given assistance with getting off stretcher/chair if needed for 4 hours after nerve block placement. Strength testing of target nerve groups in lower extremity will be confirmed before subject is allowed to walk independently. Subjects gait and walking will be assessed and confirmed to be ambulating safely before discharge.
- Conditions
- Compartment Syndrome of Leg, Healthy
- Being tested
- Mepivacaine Injection
- Keywords
- Healthy volunteer, Regional anesthesia, Compartment Syndrome
- Medical subject headings
- Compartment Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mepivacaine InjectionDrug
Also called Prilocaine
Injection of 0.375% mepivacaine in nerve block
Mepivacaine InjectionDrug
Also called Prilocaine
Injection of 1.5% mepivacaine in nerve block
| Study group | Role | What they receive |
|---|---|---|
| Leg 1 ACB + low dose SNB-PF | Experimental | Right leg and 0.375% mepivacaine popliteal fossa-sciatic Receives: Drug: Mepivacaine Injection |
| Leg 1 ACB + high dose SNB-PF | Experimental | Right leg and 1.5% mepivacaine popliteal fossa-sciatic Receives: Drug: Mepivacaine Injection |
| Leg 2 ACB + low dose SNB-PF | Experimental | Left leg and 0.375% mepivacaine popliteal fossa-sciatic Receives: Drug: Mepivacaine Injection |
| Leg 2 ACB + high dose SNB-PF | Experimental | Left leg and 1.5% mepivacaine popliteal fossa-sciatic Receives: Drug: Mepivacaine Injection |
| Leg 1 ACB only | Experimental | Right leg and 1.5% mepivacaine ACB Receives: Drug: Mepivacaine Injection |
| Leg 2 ACB only | Experimental | Left leg and 1.5% mepivacaine ACB Receives: Drug: Mepivacaine Injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pressure-pain threshold and tolerance
Pressure (mmHg) in cuff corresponding to pain score 4, 6, 8, and 10 out of 10 based on visual analog scale (VAS)
Measured: 2 hours
Ischemic pain threshold and tolerance
Cuff inflation to predetermined pressure (mmHg) corresponding to pain score of 4, 6, 8, and 10 out of 10 based on pressure-pain threshold, and held for up to 5 minutes. Pain scores recorded every 30 seconds, pain scores every 1minute with passive stretch of the gastrocnemius.
Measured: 2 hours
Ultrasound measurement of pressure in compartment in leg
Measurement of ultrasonographic qualities of compartments in the leg using both standard imaging as well shear wave elastography in response to varying external pressure of probe (0-22mmHg) using an external load sensor attached to the probe handle during pressure testing and block recovery, in the absence and presence of a thigh cuff set to 70 mmHg (non-painful pressure).
Measured: 1 hour
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Oct 2019
- Study start29 Sep 2020
- Primary completion6 Apr 2021
- Study completion6 Apr 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Compartment Syndrome of LegStudies of the same condition, open and under way.
- More trials run by Brigham and Women's HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Our patients will be randomized to one of six arms.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 42 participants (actual)
Sponsor and investigators
- Lead sponsor
- Brigham and Women's Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Massachusetts Institute of Technology
- Responsible party
- Principal investigator, Kristin Schreiber, Brigham and Women's Hospital
- Investigators
- Kristin Schreiber, MD/PhD, Principal investigator, Brigham and Women's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04113954
- Sponsor's protocol ID
- 2019P002781
- Status last verified
- May 2021
- First submitted
- 1 Oct 2019
- Last updated
- 14 May 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Chen YK, Lirk P, Flowers KM, Colebaugh CA, Wilson JM, Zeballos J, Von Keudell A, Barrett KE, Vlassakov K, Schreiber KL. Impact of varying degrees of peripheral nerve blockade on experimental pressure and ischemic pain: adductor canal and sciatic nerve blocks in a human model of compartment syndrome pain. Reg Anesth Pain Med. 2022 Jul 20:rapm-2022-103671. doi: 10.1136/rapm-2022-103671. Online ahead of print.
PubMed 35858717
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Detecting Compartment Syndrome Pain in the Presence of Regional Anesthesia in Healthy Volunteers
- ClinicalTrials.gov ID
- NCT04113954
- Acronym / sponsor ID
- 2019P002781
- Conditions
- Compartment Syndrome of Leg, Healthy
- Keywords
- Healthy volunteer, Regional anesthesia, Compartment Syndrome
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 42 participants (actual)
- Lead sponsor
- Brigham and Women's HospitalUniversity, hospital or other
- Collaborators
- Massachusetts Institute of Technology
- Study start
- 29 Sep 2020 (actual)
- Primary completion
- 6 Apr 2021 (actual)
- Study completion
- 6 Apr 2021 (actual)
- First posted
- 3 Oct 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of the study is to determine how different types of Regional Anesthesia (nerve blocks) can be helpful to patients with lower extremity trauma who develop compartment syndrome (an increased pressure in the fascial compartments) which can occur after injury to the leg.
This is a prospective, randomized study in healthy volunteers, who will undergo testing of the leg using a cuff inflation system, involving quantitative sensory testing (QST), questionnaire completion, with ultrasound scanning and nerve blocks in a supervised, monitored setting (BWH Clinical Investigation Center).
Specific Aims
- Determine the effect of adductor canal-saphenous nerve block (ACB) and popliteal-fossa nerve block (SNB-PF) vs no block on pressure and ischemic pain in a model of compartment syndrome.
- Hypothesis: There will be minimal or no change in pressure pain threshold and tolerance and pain ratings with ACB alone
- Hypothesis: There will be an increase in pressure pain threshold and tolerance and decrease in pain ratings with ACB plus popliteal-fossa nerve block (SNB-PF), compared to no block
- Determine the concentration dependence of SNB-PF effect on pressure and ischemic pain by comparing increasing doses of local anesthetic.
- Hypothesis: There will be a greater increase in pressure pain threshold and tolerance and great decrease in pain ratings with 1.5% mepivacaine than with 0.375% mepivacaine.
Detailed description
Please complete the survey (copy and paste into new link). https://redcap.partners.org/redcap/surveys/?s=D4A4TN9TDL We will not contact you if the survey is incomplete.
Please contact us via email (ykchen@partners.org) about this study with subject line "Interested in participating in Compartment Syndrome Study"
Screening and Enrollment:
Healthy volunteers will be recruited, and all interested individuals will be invited to contact study staff to hear more about the study requirements and undergo a brief phone screen to determine eligibility. After their initial phone screen with study staff, interested subjects meeting eligibility requirements will be provided with an electronic copy of the consent form, perform a video consent, and schedule a study visit, to be conducted in the Clinical Investigation Center at Brigham and Women's Hospital. A 5 hour, 1 office visit is required.
All subjects will also undergo a survey-based COVID screen within 24 hours prior to the study.
Study day:
Immediately upon arrival for their study appointment, the physician investigator will go through the consent form in detail with each potential participant, and they will also be given a chance to read it thoroughly and have questions answered. Special care will be taken during the consent process to ensure subjects are fully competent and understand the nature of the questionnaires and testing procedures, including a brief demonstration of the devices and testing done. If agreeable to the study procedures after having questions answered, participants will provide informed consent. Each participant will be assigned a random ID number, and data will be collected, entered, and analyzed by ID number only. The subject's status as a patient will be unaffected by his/her decision to participate. If subject decides against participation at this point, they will be reimbursed for their time ($20).
Enrolled participants will complete basic deidentified demographic, clinical, psychosocial, and pain questionnaires. Brief validated questionnaires will include the PROMIS anxiety, depression, and sleep disturbance short forms, Pain Catastrophizing Scale (PCS), situational pain catastrophizing scale (sPCS), Brief Symptom Index, Fibromyalgianess scale, Brief Pain Inventory, Positive and Negative Affect Schedule, and pain coping strategies questionnaire.
After completing questionnaires, subjects will lie on a stretcher, with head of bed elevated to 30-45 degree angle according to comfort, with legs and feet exposed for testing.
QST testing Pressure pain threshold: Pressure algometry is the most commonly used test for static mechanical pressure sensation in the skin and in deep tissues. Pressure algometers deliver a firm and quantifiable pressure through a flat base applied to the skin. The electronic pressure algometer that we will use (Wagner Instruments) is a hand-held algometer utilizing a pressure-sensitive strain gauge, covered by a 0.5 cm2 circular probe. The probe is covered with a soft polypropylene disk, to avoid injury to the skin. The pressure applied through the probe is transduced, amplified, and converted to electrical reading on a digital display. The pressure will be slowly increased (1 lb/s) and the participant will be asked to note when they first feel pain and when they want the pressure to stop , which will be recorded as the pressure pain threshold and tolerance, respectively.120 This process will be repeated on the trapezius and the forearm, alternating between sides of the body with 20 seconds between measurements.
Pin Prick: This tests the detection and intensity of sharp type pain. In addition, it is often used as a modality to test temporal summation of pain with repeated stimuli. The conductor of the test will touch the participant on the finger with weighted mechanical probes in ascending order (64 mN, 128 mN, 256 mN, 512 mN), making sure to keep the probe perpendicular to the skin, and allowing the full weight to be resting on this point (i.e. the weight moves within the barrel), but without touching the barrel/cylinder itself to the skin. The participant will be instructed to rate the pain (0-10) of each stimulation. The conductor will make note of the lowest weight pin prick the participant indicated caused a 1-3 out of 10 pain. Then the conductor will perform the test of temporal summation to repeated punctate stimuli, which is considered an index of central pain-faciliatory processes. The pin prick weight that the participant noted was a 1-3 out of 10 pain is applied to the skin of the dorsal fingers at a frequency of 1Hz. Ten stimuli are applied, and the patient will be asked to rate the sensation of pain from the fifth, and tenth stimulus, as well as 15 seconds after the end of the stimulus train (PAS). The wind-up phenomenon occurs with progressive increase evoked pain with repeated stimulation and represents an index of central sensitization. Testing order will be performed on each hand, bilaterally, and on each foot.
Pressure Pain Threshold Assessment:
Pressure pain will be assessed through response to cuff pressure algometry (CPA). Tonic, deep-tissue, mechanical stimulation will be applied using a Hokanson rapid cuff inflator, which allows specific calibrated pressures to by administered and held for defined time periods. Using an adjustable cuff (similar to standard blood pressure cuff) wrapped around the leg, centered around the largest diameter of the gastrocnemius muscle, pressure will be increased by turning a manual dial at a rate of approximately 10-20 mmHg/second until the subject first feels pressure, and thereafter at approximately 5-10 mmHg/s, at which time subject will be asked to note when they first start feeling pain and then when they feel as though the pain is a 4, 6, 8 and 10 out of 10 VAS score (0 = no pain, 10 = worst pain), after which the cuff will be immediately deflated. Participants will be given a break. Cuff pressure at each of these points will be recorded 3 times for each leg to determine baseline pain thresholds.
Ischemic Pain Assessment:
The cuff will be re-inflated to the subject's average pressure previously determined to produce 4 out of 10 pain for that leg, and held for 5 minutes. A pulse oximeter will be placed on the big toe to monitor ischemia (pulse oximetry wave expected to disappear). Subjects will be asked for pain score at rest every 30 seconds, and pain score on passive stretch of gastrocnemius every 60 seconds. The participant will be reminded immediately before cuff inflation that they may ask for the pressure cuff to be deflated at any time, in which case this time will be recorded. Subjects will be asked to indicate the presence of tingling (paresthesias), and will rate pain at rest 30 and 60 seconds following cuff deflation (painful after sensations), as well as pain with passive stretch of gastrocnemius at 60 seconds after cuff deflation.
There will be a 1 minute break, then the cuff pressure will be inflated to a pressure corresponding to the next pain level as initially identified on the averaged baseline testing (ex: if pressure 4/10 was 100 mmHg and 6/10 was 150 mmHg, cuff pressure will first be held at 100 mmHg and held for 5 minutes, followed by a 1 minute break, and then reinflated at 150 mmHg and held for 5 minutes, followed by 1 minutes break, etc.). The above procedure will be repeated for cuff pressure at 6/10, 8/10, and 10/10. This will be done first on the "control leg" and then on the "block leg" prior to the nerve block placement. Subjects will be reminded that they may discontinue the cuff inflation at any point, and the time of cuff inflation recorded.
IV placement:
A 20 g IV will be placed prior to the start of any nerve block procedure. Site of IV placement will be cleaned with alcohol swab and initially anesthetized with 1% lidocaine administered through a small needle to allow greater comfort with IV placement.
Nerve Blocks:
Saphenous Nerve Block (ACB):
Subjects will lie supine with block leg slightly abducted. Standard monitors will be applied for vital monitoring (continuous pulse oximetry, EKG, blood pressure cuff every 5 minutes), and this monitoring continued until 20 minutes after block completion. Using sterile technique (cleaning of skin with chloroprep, sterile gloves, mask, sterile cap, sterile needle, sterile ultrasound probe cover and sterile gel), an ultrasound-guided approach will be used to identify the saphenous nerve and surrounding sonographic landmarks (sartorius muscle, vastus medialis, femoral artery, femoral vein, and adductor magnus). With a small needle, a small skin wheal of 1 cc of 1% lidocaine will be used to anesthetize the skin. Afterwards a standard 21 g, 10 cm block needle will be inserted and directed under ultrasound guidance to the saphenous nerve location. Aspiration on block syringe will be performed to confirm that needle tip is not within a vascular structure to avoid intraarterial or venous injection of local anesthetic. Incremental injection (5 cc at a time) of 1.5% mepivacaine will follow, with a total of 10 cc (150 mg) deposited around the saphenous nerve.
Popliteal sciatic Nerve Block (SNB-PF): (for dual nerve block group only) Participant will lie supine, with leg elevated to allow access to posterior leg for US scanning. Using sterile technique, an ultrasound-guided approach will be used to identify the common peroneal nerve and tibial nerve at the level of the popliteal fossa, and surrounding sonographic landmarks (femur, popliteal artery, and popliteal vein). The common peroneal and tibial nerves will be followed proximally by scanning proximally along the leg with the ultrasound until they form a unitary nerve (sciatic). With a small needle, a small skin wheal of 1 cc of 1% lidocaine will be used to anesthetize the skin of the lateral level at this level. Afterwards a standard 21 g, 10 cm block needle will be inserted and directed under ultrasound guidance to the sciatic nerve. Aspiration on block syringe will be performed to confirm that needle tip is not within a vascular structure to avoid intraarterial or venous injection of local anesthetic. Incremental injection (5 cc at a time) of 0.375% or 1.5% mepivacaine will follow, with a total of 15 cc (56.25 mg or 225 mg) deposited around the sciatic nerve.
Expected timeline Pressure pain threshold assessment will take approximately 3 minutes and Ischemic pain assessment approximately 30 minutes (5 minutes per inflation pressure with 1 minute for rest in between). Each assessment will be taken at baseline and 20 minutes after nerve block completion to allow full effect. Ultrasound measures of compartment pressures will be assessed before, during, and after pressure and ischemic pain assessment.
Resolution of Nerve block: Nerve blocks with mepivacaine are expected to be resolved within 4-6 hours, but monitoring will continue beyond this time as some normal variation in resolution may occur between individuals. Subjects will only be given assistance with getting off stretcher/chair if needed for 4 hours after nerve block placement. Strength testing of target nerve groups in lower extremity will be confirmed before subject is allowed to walk independently. Subjects gait and walking will be assessed and confirmed to be ambulating safely before discharge.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 6
- Model description
- Our patients will be randomized to one of six arms.
| Arm | Type | Receives |
|---|---|---|
| Leg 1 ACB + low dose SNB-PF | Experimental | Drug: Mepivacaine InjectionRight leg and 0.375% mepivacaine popliteal fossa-sciatic |
| Leg 1 ACB + high dose SNB-PF | Experimental | Drug: Mepivacaine InjectionRight leg and 1.5% mepivacaine popliteal fossa-sciatic |
| Leg 2 ACB + low dose SNB-PF | Experimental | Drug: Mepivacaine InjectionLeft leg and 0.375% mepivacaine popliteal fossa-sciatic |
| Leg 2 ACB + high dose SNB-PF | Experimental | Drug: Mepivacaine InjectionLeft leg and 1.5% mepivacaine popliteal fossa-sciatic |
| Leg 1 ACB only | Experimental | Drug: Mepivacaine InjectionRight leg and 1.5% mepivacaine ACB |
| Leg 2 ACB only | Experimental | Drug: Mepivacaine InjectionLeft leg and 1.5% mepivacaine ACB |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age ≥ 18 years old, ≤ 65 years old
- BMI < 35
- Able to speak and understand English
- Willingness to undergo psychophysical testing
- Willingness to have nerve block performed
Key exclusion criteria (10 listed)
- Ongoing acute or chronic pain in lower extremities
- Diagnosis of neuropathy
- Diagnosis of diabetes
- History of chronic opioid use (having an opioid prescription > 30 days)
- Loss of any limb
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mepivacaine InjectionAlso: PrilocaineInjection of 0.375% mepivacaine in nerve block | Drug | Leg 1 ACB + high dose SNB-PF, Leg 1 ACB + low dose SNB-PF, Leg 2 ACB + high dose SNB-PF, Leg 2 ACB + low dose SNB-PF |
| Mepivacaine InjectionAlso: PrilocaineInjection of 1.5% mepivacaine in nerve block | Drug | Leg 1 ACB + high dose SNB-PF, Leg 1 ACB + low dose SNB-PF, Leg 1 ACB only, Leg 2 ACB + high dose SNB-PF, Leg 2 ACB + low dose SNB-PF, Leg 2 ACB only |
Primary outcome
Pressure-pain threshold and tolerance
Time frame: 2 hours
Pressure (mmHg) in cuff corresponding to pain score 4, 6, 8, and 10 out of 10 based on visual analog scale (VAS)
Ischemic pain threshold and tolerance
Time frame: 2 hours
Cuff inflation to predetermined pressure (mmHg) corresponding to pain score of 4, 6, 8, and 10 out of 10 based on pressure-pain threshold, and held for up to 5 minutes. Pain scores recorded every 30 seconds, pain scores every 1minute with passive stretch of the gastrocnemius.
Ultrasound measurement of pressure in compartment in leg
Time frame: 1 hour
Measurement of ultrasonographic qualities of compartments in the leg using both standard imaging as well shear wave elastography in response to varying external pressure of probe (0-22mmHg) using an external load sensor attached to the probe handle during pressure testing and block recovery, in the absence and presence of a thigh cuff set to 70 mmHg (non-painful pressure).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2021.
- Derived from this study: PubMed 35858717Chen YK, Lirk P, Flowers KM, Colebaugh CA, Wilson JM, Zeballos J, Von Keudell A, Barrett KE, Vlassakov K, Schreiber KL. Impact of varying degrees of peripheral nerve blockade on experimental pressure and ischemic pain: adductor canal and sciatic nerve blocks in a human model of compartment syndrome pain. Reg Anesth Pain Med. 2022 Jul 20:rapm-2022-103671. doi: 10.1136/rapm-2022-103671. Online ahead of print.
- Individual participant dataSharing planned: No
Related trials for Compartment Syndrome of Leg
Recruiting
Physiotherapy or Fasciotomy as Treatment for Chronic Exertional Compartment Syndrome in the Lower Leg?
Compartment Syndrome Nontraumatic Lower Leg
Recruiting
Treatment of Lower Leg Anterolateral Chronic Exertional Compartment Syndrome With Intra-muscular Botulinum Injections.
Chronic Exertional Compartment Syndrome
Recruiting
Continuous Compartment Pressure Monitoring for Compartment Syndrome in VA-ECMO Patients
Compartment Syndrome of Leg, Extracorporeal Membrane Oxygenation Complication
Recruiting
Evaluation of the Diagnostic and Therapeutic Value of Tissue Ultrafiltration in Patients at Risk of Acute Compartment Syndrome (ACS)
Acute Compartment Syndrome, Fracture, Bone
RecruitingObservational study
Can Near-Infrared Spectroscopy (NIRS) or Intramuscular Glucose Levels Detect Impaired Leg Compartment' Perfusion?
Compartment Syndromes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kristin Schreiber, MD/PhD principal investigator
Brigham and Women's Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Mepivacaine Injection in people with Compartment Syndrome of Leg and Healthy, run by Brigham and Women's Hospital at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 May 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pressure-pain threshold and tolerance (time frame: 2 hours). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04113954, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2021.